Premium
Erythrocytosis and Dialysis
Author(s) -
Shalhoub Robert J.
Publication year - 1988
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.1988.tb00734.x
Subject(s) - medicine , hematocrit , hemodialysis , gastroenterology , dialysis , renal function , population , alkaline phosphatase , peritoneal dialysis , urology , surgery , environmental health , biochemistry , chemistry , enzyme
A 63‐year‐old black man on chronic hemodialysis for 9 years has developed erythrocytosis. His hematocrit was 17–21% during the first 2 years of dialysis rising to between 30 and 40% by the 5th year and reaching 52–56% recently. He does not smoke, has not been transfused since his first year of treatment, and has not received anabolic steroids. Liver function tests generally show borderline high SGOT and SGPT with normal alkaline phosphatase, bilirubin, and prothrombin time. Hepatitis B surface antigen is negative. Abdominal CT showes no organomegaly or abnormalities except for the kidneys which, on ultrasound, show diffuse cystic changes. Arterial oxygen saturation is normal and platelet and leukocyte counts are normal. His renal failure is due to chronic glomerulonephritis and he is anuric. What is currently known about erythrocytosis in the chronic dialysis population?